Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs ACETIC ACID W/ HYDROCORTISONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Treatment of superficial bacterial infections of the external auditory canal (otitis externa) and associated inflammation.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Acetic acid is metabolized via the Krebs cycle to carbon dioxide and water. Hydrocortisone is primarily metabolized in the liver.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Hydrocortisone: ~90% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid: negligible binding.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Hydrocortisone: Vd ~0.3–0.5 L/kg (systemic); topical application results in negligible systemic distribution.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Topical: ~1–5% of hydrocortisone absorbed through intact skin; higher with inflamed skin or occlusion. Acetic acid: negligible systemic absorption.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment required for acetic acid. Hydrocortisone is minimally affected by renal impairment; no specific adjustment recommended.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
No dose adjustment required for acetic acid. For hydrocortisone, use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reducing frequency or dose, though no specific guidelines exist.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Safety and efficacy not established in pediatric patients; use not recommended.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No specific dose adjustment required. Use caution due to potential skin atrophy and systemic absorption; limit duration to minimum effective course.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Not applicable.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
For otic use only; not for ophthalmic or systemic use.,Prolonged use may lead to fungal or bacterial superinfection.,Discontinue if irritation or sensitization develops.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Hypersensitivity to any component.,Viral or fungal infections of the external ear (e.g., herpes simplex, varicella).,Perforated tympanic membrane (risk of ototoxicity).
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
No clinically relevant food interactions. No specific dietary restrictions.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed with topical use. Systemic absorption is minimal with small-area application. Avoid prolonged use on large areas, occlusive dressings, or high-potency steroids. Acetic acid has no known teratogenic risk.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Minimal systemic absorption of topical hydrocortisone and acetic acid; unlikely to affect the breastfed infant. Use on limited areas, avoid application to breast or nipple area. M/P ratio not established.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
No dosing adjustments required for pregnancy. Use lowest effective dose for shortest duration to minimize systemic absorption.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Combination otic suspension for external otitis. Ensure tympanic membrane is intact before use; perforation risks ototoxicity. Shake well before instillation. Use for no longer than 10 days to avoid fungal overgrowth or adrenal suppression. Warm bottle in hands to avoid caloric vertigo. Contraindicated in viral or fungal infections of the ear canal.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
For ear use only. Do not swallow or put in eyes.,Lie on side with affected ear upward for 5 minutes after instillation.,Keep ear clean and dry while using the medication.,Complete full course even if symptoms improve.,Do not use if you have a perforated eardrum; seek medical evaluation first.,Shake the bottle well before each use.
No interactions on record
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs ACETIC ACID W/ HYDROCORTISONE, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. ACETIC ACID W/ HYDROCORTISONE is a Corticosteroid that works by Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and ACETIC ACID W/ HYDROCORTISONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of ACETIC ACID W/ HYDROCORTISONE is: 1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and ACETIC ACID W/ HYDROCORTISONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. ACETIC ACID W/ HYDROCORTISONE is classified as Category D/X. Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.